{"analyses":[{"ciLowerLimit":"0.74","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.12","groupDescription":"Stratified analysis based on the strata of IC levels per IxRS, the number of prior chemotherapy regimens per IxRS, and histology per eCRF.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.3806","paramType":"Hazard Ratio (HR)","paramValue":"0.91","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.74","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.10","groupDescription":"Unstratified Analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.3249","paramType":"Hazard Ratio (HR)","paramValue":"0.91","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.9","upperLimit":"4.3","value":"4.1"},{"groupId":"OG001","lowerLimit":"2.6","upperLimit":"4.0","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"241"}],"units":"Participants"}],"description":"PFS is defined as the time between the date of randomization and the date of first documented PD or death, whichever occurs first. Participants who are alive and have not experienced PD at the time of analysis were censored at the time of the last tumor assessment. Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel 75 milligrams per square meter (mg/m\\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG000","title":"Docetaxel"},{"description":"Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG001","title":"Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"The TC1/2/3 or IC1/2/3 subgroup of PP","reportingStatus":"POSTED","timeFrame":"Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)","title":"PFS as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP","type":"SECONDARY","unitOfMeasure":"Months"}